SCHEMBL4348385

SCHEMBL4348385

CCOC(=O)c1ccc(-c2n[nH]c3nc(-c4ccc(NC(C)=O)cc4)ccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.51
TTK P33981 1/20 0.49
MAPK8 P45983 1/20 0.49
HPGD P15428 2/20 0.48
RECQL P46063 1/20 0.48
RAB9A P51151 5/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GAA P10253 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
POLB P06746 2/20 0.44
PRNP P04156 1/20 0.44
TSHR P16473 1/20 0.44
TP53 P04637 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
USP2 O75604 1/20 0.43
HKDC1 Q2TB90 1/20 0.43
MAPT P10636 3/20 0.43
RXFP1 Q9HBX9 2/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4349663 0.91 KDM4E (0.59) KDM4ERAB9AL3MBTL1MEN1KMT2A
SCHEMBL12340070 0.89 TTK (0.50) KDM4ETTKMAPK8KMT2ATSHR
SCHEMBL12035329 0.88 KDM4E (0.56) KDM4ERAB9AGAAMEN1KMT2A
SCHEMBL11939094 0.88 KDM4E (0.56) KDM4ERAB9AL3MBTL1POLBTP53
SCHEMBL12035436 0.87 KDM4E (0.55) KDM4ERAB9AL3MBTL1MEN1KMT2A
SCHEMBL4352101 0.86 KDM4E (0.54) KDM4EHPGDRAB9AL3MBTL1MEN1
SCHEMBL4362439 0.86 KDM4E (0.54) KDM4ETP53MAPTMAPK1
SCHEMBL12035332 0.86 TTK (0.48) KDM4ETTKMAPK8HPGDRAB9A
SCHEMBL4349388 0.85 MAPT (0.54) KDM4ERAB9AL3MBTL1GAAMEN1
SCHEMBL4348111 0.84 KDM4E (0.50) KDM4ETTKMAPK8HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110312992-A1 Inhibitors of C-Kit and Uses Thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-12-22 US claimed
US-20120302565-A1 KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF M.D. ANDERSON CANCER CENTER (US) 2012-11-29 US disclosed
US-8268809-B2 Kinase inhibitors for preventing or treating pathogen infection and method of use thereof EMORY UNIVERSITY (US) 2012-09-18 US disclosed
US-20110312992-A1 Inhibitors of C-Kit and Uses Thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-12-22 US disclosed
US-20100249122-A1 Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof EMORY UNIVERSITY (US) 2010-09-30 US disclosed
US-20090281115-A1 INHIBITORS OF C-KIT AND USES THEREOF Board of Regents, The University of Texas System, a Texas University (US) 2009-11-12 US disclosed
US-20090281115-A1 INHIBITORS OF C-KIT AND USES THEREOF Board of Regents, The University of Texas System, a Texas University (US) 2009-11-12 US disclosed
WO-2008005877-A2 INHIBITORS OF C-KIT AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249122-A1 Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof MAP3K1, MAP3K2, MAP3K6 KDM4E 1924/4885TTK 147/4885MAPK8 96/4885
US-20110312992-A1 Inhibitors of C-Kit and Uses Thereof KIT, CHUK, MASTL KDM4E 702/4885TTK 214/4885MAPK8 446/4885
US-20120302565-A1 KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF MAP3K1, MAP3K2, MAP3K6 KDM4E 1924/4885TTK 147/4885MAPK8 96/4885
US-20090281115-A1 INHIBITORS OF C-KIT AND USES THEREOF KIT, CHUK, MASTL KDM4E 702/4885TTK 214/4885MAPK8 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.